drugset / Trial / NCT02493322
Efficacy and Safety of Olmesartan Associated With Chlorthalidone in Essential Arterial Hypertension Control
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate the non-inferiority clinical efficacy of two different drug associations in the essential hypertension control.
Timeline
- Start
- —
- Primary completion
- 2025-06-01
- Completion
- —
Outcome
Outcome not reported
Stopped: “Decided by Sponsor”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Chlorthalidone | Other / unclassified | 12.5 mg | — |
| Subject | Chlorthalidone | Other / unclassified | 25 mg | — |
| Subject | Hydrochlorothiazide | Unknown | 12.5 mg | — |
| Subject | Olmesartan | Other / unclassified | 20 mg | — |